It's difficult to call a stock with an EV/EBITDA ratio in the 20's and more than a dozen active sell-side analysts "undiscovered", but I'm surprised at the relative level of chatter about Volcano (NASDAQ:VOLC) in comparison to names like Intuitive Surgical (NASDAQ:ISRG), MAKO Surgical (NASDAQ:MAKO), or Abiomed (NASDAQ:ABMD). While Volcano arguably suffers from the fact that its addressed markets have been around quite a bit longer, I believe growth-oriented investors ought to take another look at some of the possibilities of Volcano finding a new level of market acceptance and growth in the coming years.
A Clearer Picture Means Better Outcomes
Volcano has long been in the business of intravascular imaging, specifically...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|